Who owns Nasonex?
Nasonex is made and sold by Perrigo (Ireland, NYSE: PRGO) under licence, an arrangement in place since 2018; Perrigo does not own the name.[1] The Nasonex name is owned by Merck Sharp & Dohme.
Key facts
- Licensed to
- Perrigo Company plc verified
- Since
- Headquarters
- 🇮🇪 Ireland, Dublin
- Origin
- 🇺🇸 United States
- Founded
- 1997
- Category
- Consumer health › Over-the-counter medicine › Cold
- Parent ticker
- NYSE: PRGO
- Last verified
- · 1 sources
About Nasonex
Nasonex is a mometasone nasal spray for allergic rhinitis that moved from prescription to over-the-counter sale, one of a series of such switches Perrigo has acquired rights to as brands come off prescription. A prescription-to-pharmacy switch typically extends a brand's commercial life well beyond the expiry of its patents.
Ownership timeline of Nasonex
Where Nasonex sits in Perrigo
Controlling ownership as of . Brands grouped under the entity that owns them; large groups are collapsed.
Open the full Perrigo ownership tree →
Other brands handled by Perrigo
Latest news about Nasonex
No tagged news items yet. Deals, regulatory actions and recalls are added from SEC filings, regulators and trade press; only titles and links are stored.
Headlines link to the original publisher. Brandtree does not reproduce article text.
Frequently asked questions
Who makes Nasonex?
Perrigo makes and sells Nasonex under a licensing agreement that has been in place since 2018.
Does Perrigo own Nasonex?
No. Perrigo holds a licence to make and sell Nasonex, which is not the same as owning it.
Where did Nasonex come from?
Nasonex originated in the United States in 1997.
Sources (1) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
- [1] Perrigo Company plc Annual Report on Form 10-K filed 2026-02-26 — SEC EDGAR, SEC Form 10-K, published 26 February 2026; retrieved 16 September 2026.
Report a correction Opens a pre-filled GitHub issue. See our corrections policy.